Literature DB >> 1720879

Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride.

R E See1.   

Abstract

The release and metabolism of dopamine (DA) in the striatum of rats during long-term haloperidol administration (32 weeks) was assessed using in vivo microdialysis. Basal levels of homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) were significantly elevated over control values, while basal DA release was not significantly increased. The specific DA D2 receptor antagonist, raclopride (0.5 mg/kg, i.p.), increased DA release and metabolism in control animals, but this effect was profoundly blocked in the haloperidol treated group. These results suggest that chronic haloperidol treatment may induce compensatory increases in basal DA activity even though response to an acute D2 antagonist shows significant tolerance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720879     DOI: 10.1016/0304-3940(91)90477-b

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

Review 1.  Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine.

Authors:  M F Egan; S Chrapusta; F Karoum; B K Lipska; R J Wyatt
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia.

Authors:  Hiroko Hori; Takahiro Shinkai; Chima Matsumoto; Osamu Ohmori; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

3.  Effects of chronic haloperidol and/or clozapine on oxidative stress parameters in rat brain.

Authors:  Fabiano R Agostinho; Luciano K Jornada; Nadja Schröder; Rafael Roesler; Felipe Dal-Pizzol; João Quevedo
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

4.  Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid.

Authors:  Pattipati S Naidu; Amanpreet Singh; Shrinivas K Kulkarni
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

5.  Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia.

Authors:  Takahiro Shinkai; Osamu Ohmori; Chima Matsumoto; Hiroko Hori; James L Kennedy; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

6.  Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.

Authors:  Santhrani Thaakur; G Himabindhu
Journal:  J Neural Transm (Vienna)       Date:  2009-05-15       Impact factor: 3.575

7.  Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices.

Authors:  J Fang; P H Yu
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

8.  What were they thinking? Cognitive states may influence [11C]raclopride binding potential in the striatum.

Authors:  Karmen K Yoder; David A Kareken; Evan D Morris
Journal:  Neurosci Lett       Date:  2007-12-03       Impact factor: 3.046

9.  Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia.

Authors:  J L Neisewander; E Castañeda; D A Davis
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.